Key Points
- Insider buying: Daniel Wells purchased 14,760 Venture Life Group shares at GBX 68 each, worth £10,036.80, after acquiring an additional 38,717 shares the previous day for £25,166.05.
- Stock performance: Shares opened at GBX 68, up 3.8%, with a market capitalization of approximately £81.63 million and a 52-week trading range of GBX 52 to GBX 72.
- Financial results: Venture Life Group reported quarterly EPS of GBX 4.10, alongside a 7.82% return on equity and a 17.42% net margin.
Venture Life Group plc (LON:VLG - Get Free Report) insider Daniel Wells purchased 14,760 shares of the stock in a transaction dated Thursday, October 1st. The shares were purchased at an average price of GBX 68 per share, with a total value of £10,036.80.
Daniel Wells also recently made the following trade(s):
- On Wednesday, September 30th, Daniel Wells acquired 38,717 shares of Venture Life Group stock. The stock was purchased at an average cost of GBX 65 per share, with a total value of £25,166.05.
Venture Life Group Trading Up 3.8%
Shares of LON VLG opened at GBX 68 on Friday. The company has a current ratio of 4.71, a quick ratio of 1.48 and a debt-to-equity ratio of 0.82. The stock has a market capitalization of £81.63 million, a PE ratio of 15.56, a PEG ratio of 5.67 and a beta of 0.23. Venture Life Group plc has a twelve month low of GBX 52 and a twelve month high of GBX 72. The stock has a fifty day simple moving average of GBX 67.37 and a 200-day simple moving average of GBX 65.08.
Venture Life Group (LON:VLG - Get Free Report) last posted its earnings results on Tuesday, September 29th. The company reported GBX 4.10 earnings per share (EPS) for the quarter. Venture Life Group had a return on equity of 7.82% and a net margin of 17.42%. On average, equities analysts forecast that Venture Life Group plc will post 6.1391542 earnings per share for the current year.
Venture Life Group Company Profile
(
Get Free Report)
Venture Life is an international consumer self-care company focused on developing and commercialising products for the global self-care market helping our consumers live a longer healthier and more rewarding life.
Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
